Effectiveness and Safety of Oral Vancomycin for the Treatment of Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis: a Systematic Review and Pooled Analysis

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Date 2025 Jan 13

PMID 39802627

Authors

Wassel Sannaa

Mazen Almasry

Mustafa Peedikayil

Alyssa A Grimshaw

Mashary Attamimi

Abdulelah AlMutairdi

Badr Al-Bawardy

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory bowel disease (IBD) occurs in up to 70%-80% of patients with primary sclerosing cholangitis (PSC). Oral vancomycin therapy (OVT) has been reported to be effective in the treatment of IBD associated with PSC (IBD-PSC).

Objectives: To examine the effectiveness and safety of OVT in the treatment of IBD-PSC by performing a systematic review and pooled analysis of the literature.

Design: We performed a systematic review and pooled analysis of studies reporting IBD clinical response to OVT in IBD-PSC.

Data Sources And Methods: A systematic search was conducted in Cochrane Library, Embase, Google Scholar, Medline, PubMed, Scopus, and Web of Science from database inception to June 3, 2024. We included adult and pediatric studies that reported on clinical response (defined as any improvement in IBD-related clinical symptoms) of IBD-PSC patients treated with OVT (including pre- and post-liver transplantation cohorts). Pooled analyses of OVT response and safety were performed.

Results: A total of 21 (open-label, non-controlled) studies including 290 patients with IBD-PSC treated with OVT were included. The median duration of OVT to treat IBD-PSC was 32.5 weeks (interquartile range (IQR): 19-83 weeks). The total daily dose of OVT ranged from 250 to 1500 mg. Concomitant treatment included the following: mesalamine in 14.5% ( = 42), advanced therapies in 10.7% ( = 31), and immunosuppressive agents in 14.1% ( = 41). Clinical response was noted in 47.6% (138/290) and clinical remission in 43.5% (100/230). The biochemical remission rate post-OVT was 68.8% (55/80) and endoscopic remission was 39.4% (80/203). Three studies ( = 11) reported no episodes of acute cholangitis while on OVT. Five studies ( = 69) reported an incidence rate of 8.7% of vancomycin-resistant enterococci post-OVT to treat IBD-PSC.

Conclusion: OVT was associated with clinical response/remission in almost half of patients with IBD-PSC with a favorable side effect profile. Further prospective randomized trials are needed to confirm the dosing, efficacy, treatment duration, and long-term safety of OVT for the treatment of IBD-PSC.

Trial Registration: The study protocol was registered with PROSPERO a priori (no. CRD42023438341).

References

Trivedi P, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J . Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020; 159(3):915-928. DOI: 10.1053/j.gastro.2020.05.049. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Kim W, Therneau T, Wiesner R, Poterucha J, Benson J, Malinchoc M . A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000; 75(7):688-94. DOI: 10.4065/75.7.688. View

Shen B . Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis. Gastroenterol Rep (Oxf). 2021; 9(3):274-275. PMC: 8309678. DOI: 10.1093/gastro/goab004. View

Hilscher M, Enders F, Carey E, Lindor K, Tabibian J . Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016; 15(2):246-53. DOI: 10.5604/16652681.1193721. View

Abraham C, Cho J . Inflammatory bowel disease. N Engl J Med. 2009; 361(21):2066-78. PMC: 3491806. DOI: 10.1056/NEJMra0804647. View

Hey P, Lokan J, Johnson P, Gow P . Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. BMJ Case Rep. 2017; 2017. PMC: 5747763. DOI: 10.1136/bcr-2017-221165. View

Dao A, Abidian M, Lestrange A, Mattar M, Rangnekar A, Charabaty A . Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis. Inflamm Bowel Dis. 2019; 25(7):e90-e91. DOI: 10.1093/ibd/izz027. View

Shah A, Pakneeshan S, Jones M, Koloski N, Callaghan G, Morrison M . How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?. Indian J Gastroenterol. 2022; 41(5):519-524. PMC: 9715441. DOI: 10.1007/s12664-022-01286-9. View

10.

Awoniyi M, Wang J, Ngo B, Meadows V, Tam J, Viswanathan A . Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC. Gut. 2022; 72(4):671-685. PMC: 9751228. DOI: 10.1136/gutjnl-2021-326500. View

11.

Kim Y, Hurley E, Park Y, Ko S . Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023; 55(7):1380-1387. PMC: 10394020. DOI: 10.1038/s12276-023-01042-9. View

12.

Abarbanel D, Seki S, Davies Y, Marlen N, Benavides J, Cox K . Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol. 2012; 33(2):397-406. PMC: 3565076. DOI: 10.1007/s10875-012-9801-1. View

13.

Kummen M, Thingholm L, Ruhlemann M, Holm K, Hansen S, Moitinho-Silva L . Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology. 2021; 160(5):1784-1798.e0. PMC: 7611822. DOI: 10.1053/j.gastro.2020.12.058. View

14.

Ricciuto A, Liu K, El-Matary W, Amin M, Amir A, Aumar M . Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium. Aliment Pharmacol Ther. 2024; 59(10):1236-1247. DOI: 10.1111/apt.17936. View

15.

Tabibian J, Weeding E, Jorgensen R, Petz J, Keach J, Talwalkar J . Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013; 37(6):604-12. DOI: 10.1111/apt.12232. View

16.

Tan L, Reilly C, Steward-Harrison L, Balouch F, Muir R, Lewindon P . Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis. Gut. 2018; 68(8):1533-1535. DOI: 10.1136/gutjnl-2018-316599. View

17.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

18.

Bowlus C, Arrive L, Bergquist A, Deneau M, Forman L, Ilyas S . AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2022; 77(2):659-702. DOI: 10.1002/hep.32771. View

19.

Cox K, Cox K . Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998; 27(5):580-3. DOI: 10.1097/00005176-199811000-00015. View

20.

Almomen H, Al-Bawardy B . Oral Vancomycin Induced and Maintained Clinical and Endoscopic Remission in Ulcerative Colitis and Primary Sclerosing Cholangitis Post-liver Transplantation. Inflamm Bowel Dis. 2023; 29(5):837-838. DOI: 10.1093/ibd/izad040. View